

Clinical Trial Protocol

Iranian Registry of Clinical Trials

28 Jul 2026

The effect of myoinositol supplementation on serum levels of Pro-oxidant Antioxidant Balance (PAB), leptin and adiponectin, nutritional status and appetite in patients with non-alcoholic fatty liver disease

Protocol summary

Study aim

to determine the effect of myoinositol supplementation on serum levels of Pro-oxidant Antioxidant Balance (PAB), leptin and adiponectin, nutritional status and appetite in patients with non-alcoholic fatty liver disease

Design

Double-blinded placebo-controlled randomized controlled trial

Settings and conduct

The volunteers being eligible to participate in the study will be randomly allocated into "Myo-inositol" or "Placebo" group and followed the intervention for 8 weeks. At the beginning and after 8 weeks, 7 cc 12-14 hour fasting blood was taken and serum samples would be used to assess liver enzymes, leptin, adiponectin and PAB.

Participants/Inclusion and exclusion criteria

Inclusion criteria: patients with NAFLD (grade 1 and 2) both sexes age 18-55 years BMI between 30-40 kg/m²
Exclusion criteria: Athlete, pregnancy, lactation and menopause Use of contraceptive pills and estrogen Smoking and alcohol drinking Use of any supplement or medications affecting liver function over last 3 months Diseases with similar pathogenesis tend to be pregnant

Intervention groups

The intervention group will take myo-inositol supplement (2 gr sachets of myo-inositol before lunch and dinner) and placebo group (2 gr sachets of maltodextrin before lunch and dinner) for 8 weeks. At the beginning of the study, both groups will be given nutritional recommendations.

Main outcome variables

Nutritional status (energy, macronutrients, micronutrients intake), Leptin and adiponectin status and their ratio, Pro-oxidant Antioxidant Balance (PAB) status, anthropometric indices (weight, BMI)- body composition (Amount and % of body FM, FFM), liver function (liver

ultrasonography and enzyme levels of ALT, AST)

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210530051441N2**

Registration date: **2022-03-12, 1400/12/21**

Registration timing: **registered_while_recruiting**

Last update: **2022-03-12, 1400/12/21**

Update count: **0**

Registration date

2022-03-12, 1400/12/21

Registrant information

Name

Mohammad Reza Shiri Shahsavari

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 28 3336 9581

Email address

nutshiri@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-03-11, 1400/12/20

Expected recruitment end date

2022-08-21, 1401/05/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effect of myoinositol supplementation on serum levels of Pro-oxidant Antioxidant Balance (PAB), leptin and adiponectin, nutritional status and appetite in patients with non-alcoholic fatty liver disease

Public title

The effect of myo-inositol supplementation on NAFLD

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Age 18-55 years Body mass index = 30-40 Kg /m2
Willingness to cooperate Hepatic steatosis based on Grade 1 and 2 NAFLD disease

Exclusion criteria:

Athlete, pregnancy, lactation and menopause in women
Smoking and drinking alcohol Adherence to a special diet or weight loss 3 months before the study Use of chemical or herbal medicines for weight loss, hepatotoxic (phenytoin, amoxifine, lithium), lipid-lowering (statins), Insulin sensitizer, corticosteroids and non-steroidal, anti-inflammatory medications and any dietary supplements for 3 months before the study History of weight loss surgery over the last year those with cardiovascular, hepatic, renal, intestinal, thyroid and parathyroid dysfunction, billiary, any known autoimmune diseases, PCOs, cancers and conditions with mal-absorption such as Sprue and Crohn Candidate or history of Liver transplant

Age

From **18 years** old to **55 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Investigator

Sample size

Target sample size: **42**

Randomization (investigator's opinion)

Randomized

Randomization description

In this study, random allocation will be performed using the r.allocation command in Stata/MP 17.0*64 software, which performs both stratification and blocking at the same time. Thus, 42 eligible patients will be classified into 8 stratas based on 3 variables: age, sex and BMI (age ("18-35" vs "36-50"), gender ("female" vs "male"), BMI ("30-35 Kg/m2" vs "35-40 Kg/m2")) and we will define these 8 stratas in the r.allocation command. Also, since we will have 2 intervention and placebo groups, we will define blocks with size 2, which will be generated automatically by the Stata software at the same time, and we will use the generated sequence for random allocation.

Blinding (investigator's opinion)

Double blinded

Blinding description

The person who packaged supplements/placebo will not be aware about the content and also has no role in the implementation and analysis of the data. None of the researchers or patients will be aware of the type of combination each person is receiving.

Placebo

Used

Assignment

Parallel

Other design features

Patients in both placebo and supplement groups will receive nutritional recommendations

Secondary Ids

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Qazvin university of medical science

Street address

Qazvin university of medical sciences, bahamor blv.

City

Qazvin

Province

Qazvin

Postal code

3419759811

Approval date

2021-11-30, 1400/09/09

Ethics committee reference number

IR.QUMS.REC.1400.340

Health conditions studied**1****Description of health condition studied**

Non-alcoholic fatty liver

ICD-10 code

K76.0

ICD-10 code description

Fatty (change of) liver, not elsewhere classified

Primary outcomes**1****Description**

serum leptin

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

ELISA method

2

Description

serum adiponectin

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

ELISA method

3

Description

Ratio of leptin to adiponectin

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

According to the formula

4

Description

Pro-oxidant Antioxidant Balance (PAB)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Enzymatic and chemical methods

5

Description

Body mass index (BMI)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

According to the formula

6

Description

Fat mass

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Using bioelectric impedance analyzer

7

Description

Energy, macronutrients and micronutrients intakes

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

a 3-days 24 hour- recall questionnaire at each phase will be completed and analyzed using Nutritionist 4 software

8

Description

Physical activity level

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Via short form of IPAQ questionnaire

9

Description

Appetite status

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Validated appetite questionnaire

10

Description

Weight

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

using Seca scale

11

Description

Fat Free mass

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Using body analyzer based on bioelectric impedance

Secondary outcomes

1

Description

Fatty liver grade

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

Ultrasonigraphy

2

Description

Alanine aminotransferase (ALT)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

enzymatic method

3

Description

Aspartate aminotransferase (AST)

Timepoint

Baseline and 8 weeks after intervention

Method of measurement

enzymatic method

Intervention groups

1

Description

Intervention group: Patients in this group will receive myo-inositol supplement and nutritional recommendation

for 8 weeks. Two 2 gr sachet of myo-inositol powder will be asked to be dissolved in a glass of water and consumed twice a day 30 minutes before lunch and dinner. As there is no specific recommendation for NAFLD we use the American Diabetes Association that recommends consuming more fruits, vegetables, whole grains and less saturated fatty acids.

Category

Treatment - Drugs

2**Description**

Placebo group: Patients in this group will receive placebo and nutritional recommendations for 8 weeks. Two 2 gr sachet of maltodextrin powder which will be asked to be dissolved in a glass of water and consumed twice a day 30 minutes before lunch and dinner.

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

Velayat hospital- Qazvin

Full name of responsible person

Mohammad Reza Shiri Shahsavar

Street address

Qazvin University of Medical Sciences, Bahonar blv,

City

Qazvin

Province

Qazvin

Postal code

3419759811

Phone

+98 28 3336 9581

Email

nutshiri@gmail.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Qazvin University of Medical Sciences

Full name of responsible person

Mohammad Reza Shiri Shahsavar

Street address

Qazvin University of Medical Sciences, bahonar blv

City

Qazvin

Province

Qazvin

Postal code

3419759811

Phone

+98 28 3336 9581

Email

nutshiri@gmail.com

Grant name

vice chancellor for research and technology of qazvin university of medical sciences

Grant code / Reference number**Is the source of funding the same sponsor organization/entity?**

No

Title of funding source

Qazvin university of medical sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Qazvin University of Medical Sciences

Full name of responsible person

Mohammad Reza Shiri Shahsavar

Position

assistant professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

قزوین بلوار باهنر دانشگاه علوم پزشکی

City

Qazvin

Province

Qazvin

Postal code

3419759811

Phone

+98 28 3336 9581

Email

nutshiri@gmail.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Qazvin University of Medical Sciences

Full name of responsible person

Mohammad Reza Shiri Shahsavar

Position

assistant professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Qazvin university of medical sciences, Bahonar blv

City

Qazvin

Province

Qazvin

Postal code

3419759811

Phone

+98 28 3336 9581

Email

nutshiri@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Qazvin University of Medical Sciences

Full name of responsible person

Zahra Alizadeh Zonouzi

Position

student

Latest degree

Bachelor

Other areas of specialty/work

Nutrition

Street address

Qazvin university of medical sciences, Bahonar blv

City

Qazvin

Province

Qazvin

Postal code

3419759811

Phone

+98 28 3336 9581

Email

z.alizadeh76@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Data collected for the primary outcomes will be shared

When the data will become available and for how long

Access starting 12 months after publication

To whom data/document is available

The data will only be available for people working in academic institutions.

Under which criteria data/document could be used

The data of the present study will only be accessible by other researchers , for conducting meta-analysis

From where data/document is obtainable

Mrs.Zahra alizadeh zonouzi, Email address:
z.alizadeh76@yahoo.com, cellphone number:
09388202522

What processes are involved for a request to access data/document

The applicant should provide a brief description of the aims and methods of his Meta-analysis . His request will be assessed and , if agreed, the data will be emailed to the applicant. All these procedures will take no longer than 15 days

Comments